DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Nucleic Acid Therapeutic Delivery (NATD).
Date: June 10–11, 2025.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Jingwu Xie, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594–8625, email: *jingwu.xie@nih.gov.*

Name of Committee: Oncology 2—Translational Clinical Integrated Review Group; Therapeutic Immune Regulation Study Section.
Date: June 12–13, 2025.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Yue Wu, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 803C, Bethesda, MD 20892, (301) 867–5309, email: *wuy25@csr.nih.gov.*

Name of Committee: Digestive, Kidney and Urological Systems Integrated Review Group; Pathobiology of Kidney Disease Study Section.
Date: June 17–18, 2025.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Atul Sahai, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2188, MSC 7818, Bethesda, MD 20892, 301–435–1198, email: *sahaia@csr.nih.gov.*

Name of Committee: Bioengineering Sciences & Technologies Integrated Review Group; Modeling and Analysis of Biological Systems Study Section.
Date: June 17–18, 2025.
Time: 9:30 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Zarana Patel, Ph.D., MPH, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 496–9295, *zarana.patel@nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: April 16, 2025.

Bruce A. George,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2025–06854 Filed 4–21–25; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of an Exclusive Patent License: Size-Dependent Brain and Lymphatic Distribution of Macromolecular Drug Delivery Platform

AGENCY: National Institutes of Health, Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents applications listed in the **SUPPLEMENTARY INFORMATION** section of this notice to Sangam Lifesciences, Inc. (Sangam), a company located in Denver, Colorado.

DATES: Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before April 22, 2025 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Whitney Hastings, Ph.D., Senior Technology Transfer Manager, NCI Technology Transfer Center, Telephone: (301)–624–1286; Email: *whitney.hastings2@nih.gov.*

SUPPLEMENTARY INFORMATION:

Intellectual Property

1. US Provisional Patent Application No. 63/037,058 filed June 10, 2020, and entitled ''Size-Dependent Brain and Lymphatic Distribution of Macromolecular Drug Delivery Platform'' [HHS Reference No. E–078–2020–0–US–01];
2. US Patent Cooperation Treaty Application No. PCT/US2021/036548 filed June 9, 2021, and entitled ''Size-Dependent Brain and Lymphatic Distribution of Macromolecular Drug Delivery Platform'' [HHS Reference No. E–078–2020–0–PCT–02];
3. U.S. National Stage Application No. 18/009,710 filed December 9, 2022, and entitled ''Size-Dependent Brain and Lymphatic Distribution of Macromolecular Drug Delivery Platform'' [HHS Reference No. E–078–2020–0–US–06];
4. Australia National Stage Application No. 2021289443 filed January 3, 2023, and entitled ''Size-Dependent Brain and Lymphatic Distribution of Macromolecular Drug Delivery Platform'' [HHS Reference No. E–078–2020–0–AU–03];
5. Canada National Stage Application No. 3186654 filed June 9, 2021, and entitled ''Size-Dependent Brain and Lymphatic Distribution of Macromolecular Drug Delivery Platform'' [HHS Reference No. E–078–2020–0–CA–04]; and
6. European Patent National Stage Application No. 21822452.5 filed January 5, 2023, and entitled ''Size-Dependent Brain and Lymphatic Distribution of Macromolecular Drug Delivery Platform'' [HHS Reference No. E–078–2020–0–EP–05].

The patent rights in these inventions have been assigned to the Government of the United States of America.

The prospective exclusive license territory may be worldwide and the field of use may be limited to the following:

''Use of the Patent Rights to develop, manufacture and commercialize a poly (L-lysine succinylated) (PLS) alpha-galactosylceramide prodrug for human and veterinary uses in the treatment of cancer.''

This technology describes a drug delivery platform comprising a negatively charged, synthetic polymer, PLS, which specifically targets scavenger receptor A1 (SR–A1). The

PLS polymer contains side chains with pendant carboxylic acids that facilitate conjugation of therapeutically active ingredients through hydrolysable ester bonds, allowing for the delivery and controlled release of drugs to SR–A1 expressing cells and tissues. Depending on the nature of the therapeutic agent conjugated to the PLS, this drug delivery platform has the potential to be widely applicable across a range of psychiatric, oncology, infections, inflammatory and neurological disorders. To date, this drug platform technology has been tested with several therapeutic agents including alpha-galactosylceramide, breflate, LD10, and HCQ.

The scope of exclusivity for this license will be limited to the PLS-alpha-galactosylceramide prodrug for the treatment of cancers. Other fields of use will still be available if this license is granted, including use of the PLS-alpha-galactosylceramide prodrug for non-oncology indications and the PLS platform conjugated to other therapeutic agents.

This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

Complete applications for a license that are timely filed in response to this notice will be treated as objections to the grant of the contemplated exclusive patent license. In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: April 14, 2025.

Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2025–06878 Filed 4–21–25; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[Docket ID: FEMA–2024–0028; OMB No. 1660–0105]

Agency Information Collection Activities: Submission for OMB Review, Comment Request; National Household Survey on Disaster Preparedness

AGENCY: Federal Emergency Management Agency, Department of Homeland Security.

ACTION: 30-day notice of reinstatement and request for comments.

SUMMARY: The Federal Emergency Management Agency (FEMA) will submit the information collection abstracted below to the Office of Management and Budget for review and clearance in accordance with the requirements of the Paperwork Reduction Act of 1995. FEMA invites the general public to take this opportunity to comment on a reinstatement, without change, of a previously approved information collection. In accordance with the requirements of the Paperwork Reduction Act of 1995, this notice seeks comments concerning the National Household Survey on Disaster Preparedness, which identifies progress and gaps in individual and community preparedness, and to better understand the motivational factors and barriers to preparedness that people face.

DATES: Comments must be submitted on or before May 22, 2025.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to *www.reginfo.gov/public/do/PRAMain*. Find this particular information collection by selecting ''Currently under 30-day Review—Open for Public Comments'' or by using the search function.

FOR FURTHER INFORMATION CONTACT: Requests for additional information or copies of the information collection should be made to Director, Information Management Division, 500 C Street SW, Washington, DC 20472, email address *FEMA-Information-Collections-Management@fema.dhs.gov* or Andrew Burrows, Preparedness Behavior Branch Chief, Individual and Community Preparedness Division, Partnership and Engagement Branch, at (202) 716–0527, and *andrew.burrows@fema.dhs.gov*.

SUPPLEMENTARY INFORMATION: The Robert T. Stafford Disaster Relief and Emergency Assistance Act (Stafford Act) (Pub. L. 93–288, as amended) (42 U.S.C. 5195–5195(a)) identifies the purpose of emergency preparedness ''for the protection of life and property in the United States from hazards.'' It directs that the Federal Government ''provide necessary direction, coordination, and guidance'' as authorized for a comprehensive emergency preparedness system for all hazards. Emergency preparedness is defined as all ''activities and measures designed or undertaken to prepare or minimize the effects of a hazard upon the civilian population . . .'' The ''conduct of research'' is among the measures to be undertaken in preparation for hazards.

The Department of Homeland Security (DHS) Strategic Plan 2020–2024 includes Goal 5 to ''strengthen preparedness and resiliency.'' The first objective (5.1) of this goal is to ''build a national culture of preparedness'' with a sub-objective to ''improve awareness initiatives to encourage public action to increase preparedness.'' Similarly, in FEMA's 2022–2026 Strategic Plan, Goal 3 is to ''promote and sustain a ready FEMA and prepared nation.''

Presidential Policy Directive-8 (PPD–8) directs the Secretary of Homeland Security to ''coordinate a comprehensive campaign to build and sustain national preparedness, including public outreach and community-based and private sector programs to enhance national resilience, the provision of Federal financial assistance, preparedness efforts by the Federal Government, and national research and development efforts.''

The Post Katrina Emergency Management Reform Act (PKEMRA) (Pub. L. 109–295) (6 U.S.C. 749(a)) requires the FEMA Administrator, in coordination with the National Council on Disability and the National Advisory Council, to establish a comprehensive system to assess, on an ongoing basis, the Nation's prevention capabilities and overall preparedness, including operational readiness.

In response to the charge to FEMA, and to the DHS and FEMA strategic priorities, FEMA manages programs to improve the public's knowledge and actions for preparedness and resilience. Information from this collection will be used to changes in knowledge, attitudes, and behaviors related to preparedness in the general public. This information collection will be in the form of a public opinion survey administered to a sample of American adults across the nation. The nature of the information collected will focus on people's attitudes, behaviors, and motivations